LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

Home・Stock List・Kura Oncology Inc

Kura Oncology Inc

Open

SectorHealthcare

9.21 -9.71

Buy Sell

Overview

Share price change

24h

Current

Min

9.16

Max

10.2

Key metrics
By Trading Economics
Income	7.7M -73M
Sales	929K 18M
EPS	-0.828
Profit margin	-401.495
Employees	260
EBITDA	7.4M -78M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+175.59% upside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	159M 1B
Previous open	18.92
Previous close	9.21

News Sentiment

By Acuity

50%

124 / 344 Healthcare

Kura Oncology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

31 May 2026, 23:44 UTC

Market Talk

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 May 2026, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

31 May 2026, 23:36 UTC

Market Talk

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 May 2026, 23:36 UTC

Market Talk

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 May 2026, 22:54 UTC

Acquisitions, Mergers, Takeovers

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 May 2026, 23:08 UTC

Acquisitions, Mergers, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 May 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 May 2026, 20:53 UTC

Earnings

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 May 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 May 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 May 2026, 20:11 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 May 2026, 19:47 UTC

Earnings

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 May 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 May 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 May 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 May 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 May 2026, 19:05 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 May 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 May 2026, 18:12 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 May 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 May 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 May 2026, 17:55 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 May 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 May 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 May 2026, 17:00 UTC

Earnings

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 May 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 May 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 May 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 May 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 May 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

175.59% upside

12 Months Forecast

Average 28.11 USD 175.59%

High 40 USD

Low 15 USD

Based on 11 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Kura Oncology Inc - Dist in the past 3 months.

Sentiment

By Acuity

124 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.